Eli Lilly & Co (LLY) stock fell by 2.63% as UBS continues to favor the company for its promising growth prospects, but market fluctuations and overall declines in U.S. equities may have influenced the stock's drop.

Eli Lilly & Co (LLY) stock fell by 2

Eli Lilly & Co. (LLY) stock fell by 5.59% due to concerns arising from rival Novo Nordisk's second reduction of its 2025 financial outlook for its weight loss drug, which may signal increased competition in the market.

Eli Lilly & Co

Eli Lilly & Co (LLY) stock rose by 1.87%, likely due to positive market sentiment surrounding pharmaceutical companies expanding their manufacturing and research in the U.S. in response to U.S. tariff policies and the push for increased domestic production, similar to recent announcements from other major pharmaceutical firms like AstraZeneca.

Eli Lilly & Co (LLY) stock rose by 1

Eli Lilly & Co (LLY) stock rose 1.87% as the pharmaceutical industry, including competitors like AstraZeneca, announced significant investments in U.S. manufacturing and research capabilities in response to potential tariff policies, signaling a commitment to domestic production and innovation.

Eli Lilly & Co (LLY) stock rose 1

Eli Lilly & Co (LLY) stock fell by 3.45% likely due to investors comparing its dividend yield and stability unfavorably against competing large-cap medical company AbbVie (ABBV), which offers a higher dividend yield and a longer track record of dividend growth.

Eli Lilly & Co (LLY) stock fell by 3

Eli Lilly & Co (LLY) stock rose 0.8% last night amid broader market declines, likely due to resilience in the pharmaceutical sector and positive market sentiment surrounding its performance, contrasting with the overall negative trends affecting other sectors.

Eli Lilly & Co (LLY) stock rose 0

Eli Lilly & Co. (LLY) stock rose by 0.8%, reaching $793.34, likely due to its high trading volume and ongoing investor interest in pharmaceutical stocks as the company continues to develop and market key diabetes and obesity medications.

Eli Lilly & Co (LLY) stock saw a slight increase of 0.47% in value, attributed to its strong market presence, robust trading volume, and investor interest in medical stocks as reflected in their high trading activity within the healthcare sector.

Eli Lilly & Co (LLY) stock saw a slight increase of 0

Eli Lilly & Co (LLY) stock saw a slight increase of 0.18%, likely due to positive market sentiment surrounding medical stocks and overall investor interest in the healthcare sector's growth potential, which includes new drug approvals and innovations.

Eli Lilly & Co (LLY) stock rose by 0.97% due to increased investor interest in medical stocks, reflecting factors like trading volume, regulatory developments, and potential breakthroughs in pharmaceuticals.

Eli Lilly & Co (LLY) stock rose by 0

Eli Lilly & Co (LLY) stock declined by 0.78% due to recent downgrades from several brokerages and mixed earnings results that fell short of analysts' expectations.

Eli Lilly & Co (LLY) stock declined by 0

Eli Lilly & Co. (LLY) stock fell by 2.02% amid news of its $1.3 billion acquisition of Verve Therapeutics, reflecting investor concerns over the high costs and uncertain market potential of gene-editing therapies, despite the deal's long-term growth prospects.

Eli Lilly & Company's (LLY) stock, which fell by 2.02%, is experiencing declines likely due to broader market trends affecting medical stocks, regulatory concerns, or competition in the healthcare sector, although specific reasons for the drop were not detailed in the article.

Eli Lilly & Company's (LLY) stock, which fell by 2

Eli Lilly & Co (LLY) stock decreased by 1.44% as it experienced fluctuations in trading volume and market conditions, reflecting investor concerns and potential sell-offs common in pharmaceutical stocks influenced by factors such as regulatory approvals and clinical outcomes.

Eli Lilly & Co (LLY) stock decreased by 1

Eli Lilly & Co. (LLY) stock rose by 0.42% due to its impressive financial performance and growth from innovative medicines, which have significantly impacted the company's success since late 2020.

Eli Lilly & Co. (LLY) stock rose 4.33% to $770.00 amid a broader focus on pharmaceutical stocks, likely driven by increasing investor interest based on the company’s strong market position and product developments in diabetes and obesity care.

Eli Lilly & Co (LLY) stock rose by 2.09% due to increased investor interest, as it was highlighted as one of the pharmaceutical stocks to watch based on high trading volumes, indicating strong market engagement and potential optimism regarding its products and business operations.

Eli Lilly & Co (LLY) stock rose by 2

Eli Lilly & Co. (LLY) stock fell by 0.8% to $713.99, likely due to broader market pressures and potential investor sentiment influenced by competing pharmaceutical stocks and general volatility within the sector.

Eli Lilly & Co (LLY) stock rose 1.61% following an upgrade from Zacks Research, which increased its Q2 2025 earnings per share estimate from $5.48 to $5.53, indicating analysts' increased confidence in the company's financial performance.

Eli Lilly & Co. (LLY) stock dropped by 1.07% amid a broader market trend and investor sentiments shifting back towards more established tech growth stories, possibly reflecting concerns about future profitability in light of competition and market saturation in the AI sector that the company is linked to through its use of AI for drug discovery.

Eli Lilly & Co. (LLY) stock experienced a decline of 0.3% amidst a volatile trading environment for pharmaceutical stocks, which can be attributed to the sector's inherent risks, including high R&D costs and regulatory pressures that affect market sentiment.

Eli Lilly & Co (LLY) stock rose 3.72% after the company reported a strong first-quarter earnings of $12.73 billion, driven by a significant increase in revenue, despite lowering its 2025 guidance. The stock's increase is likely attributed to the better-than-expected revenue that surpassed market consensus.

Eli Lilly & Co (LLY) stock rose 3

Eli Lilly and Co (LLY) stock fell by 11.66% after the company reported positive first-quarter earnings but lowered its guidance for 2025, which disappointed investors.

Eli Lilly and Co (LLY) stock fell by 11

Eli Lilly & Company (LLY) stock fell 11.66% due to competitive pressures and potential market shifts affecting the pharmaceutical sector, in contrast to other pharmaceutical companies that showed varying trading performances.

Eli Lilly & Company (LLY) stock fell 11

Eli Lilly & Co (LLY) stock rose 1.55% despite a downgrade from a "strong-buy" to a "moderate sell" rating by HSBC, as other analysts, like Truist Financial and StockNews.com, have maintained or increased their target prices and buy ratings, indicating overall bullish sentiment in the market.

Eli Lilly & Co.'s stock rose by 1.16% following positive results from its weight-loss pill, which demonstrated effectiveness comparable to Novo Nordisk's Ozempic, causing Novo Nordisk's stock to decline significantly.

Eli Lilly & Co (LLY) stock experienced a decline of -2.61% attributed to broader market trends and investment strategy adjustments by funds like Eaton Vance Worldwide Health Sciences Fund, which involves reducing positions in various health-related companies amidst fluctuating investor sentiment.

Eli Lilly & Co (LLY) stock experienced a decline of -2

Eli Lilly & Co. (LLY) stock soared 14.3% after trial data indicated its experimental weight-loss pill, orforglipron, demonstrated comparable efficacy to the popular Ozempic injection, pushing the company closer to a potential oral alternative in the obesity treatment market. The stock's increase is attributed to favorable results from the trial, showing significant weight loss and improved blood sugar levels, which could position Lilly as a leader in the evolving weight-loss drug market.

Eli Lilly & Co. (LLY) stock surged by 14.3% following positive results from late-stage trials of its oral obesity medication orforglipron, which successfully lowered blood sugar levels in patients with Type 2 diabetes and facilitated weight loss, positioning it as a potentially more convenient alternative to existing GLP-1 injection therapies.

Eli Lilly and Company (LLY) stock fell by 2.94% following a downgrade of its price target by Guggenheim from $973.00 to $928.00, despite maintaining a "buy" rating, reflecting investor concerns about potential growth amidst mixed analyst sentiments and recent earnings results that missed expectations.

Eli Lilly and Company (LLY) stock fell by 2

Eli Lilly & Co (LLY) stock rose by 0.38% following an upgrade in Q1 2026 earnings per share estimates by Zacks Research, which increased its forecast from $6.22 to $6.30, reflecting growing analyst confidence in the company's financial performance.

Eli Lilly & Co (LLY) stock rose by 3.0% following Pfizer's decision to discontinue the development of danuglipron, which may have positively influenced investor sentiment towards Eli Lilly and other companies in the sector.

Eli Lilly & Co (LLY) stock rose by 3

Eli Lilly & Co. (LLY) shares rose 3.78% amidst a heightened interest in pharmaceutical stocks driven by trading volume increases and market dynamics, likely influenced by the company's strong product pipeline and robust performance in recent trading sessions.

Eli Lilly & Co (LLY) stock rose by 0.35% due to its strong consensus rating, higher revenue and earnings compared to Exicure, and a favorable institutional ownership profile which suggests confidence from large investors in its long-term growth potential.

Eli Lilly & Co (LLY) stock fell by 3.56% amid news that Sangamo Therapeutics announced a licensing agreement with the company, which may have raised concerns among investors about the potential implications or costs associated with the deal.

Eli Lilly & Co. (LLY) stock fell by 2.5% amid concerns about potential tariffs on pharmaceuticals proposed by the Trump administration, which could disrupt existing supply chains and raise production costs for companies heavily reliant on imported ingredients.

Eli Lilly & Co (LLY) saw a decline of 0.62%, trading down to $851.85 amid fluctuations in the pharmaceutical sector influenced by trading volumes and market conditions. 

The drop in Eli Lilly & Co's stock price could be attributed to overall market trends affecting pharmaceutical stocks, as well as potential concerns regarding trading volume and market sentiment.

Eli Lilly & Co (LLY) saw a decline of 0

Eli Lilly & Co (LLY) stock experienced a decline of 0.62% last night, amidst broader market dynamics and competition in the biotech field, particularly in the context of advancements and approvals in treatments from other companies.

Eli Lilly & Co (LLY) stock experienced a decline of 0

Eli Lilly & Co (LLY) stock fell by 1.45% mainly due to a general downtrend in the healthcare sector, influenced by market dynamics and regulatory changes affecting medical stocks.

Eli Lilly & Co (LLY) stock fell by 1

Eli Lilly & Co. (LLY) stock rose by 1.76% to $826.35, likely due to strong trading volume and investor interest among pharmaceutical stocks as part of a broader trend in the healthcare sector.

Eli Lilly & Co (LLY) stock decreased by 2.46% amidst a broader decline in weight loss drug stocks due to increasing competition in the GLP-1 market, as rivals like Zealand Pharma and Roche are developing next-generation treatments with better weight-loss results, alongside regulatory changes impacting the availability of off-brand GLP-1 medications.

Eli Lilly & Co (LLY) stock decreased by 2

Eli Lilly & Co (LLY) stock fell by 0.57% despite positive clinical trial results for their partnered drug, baricitinib, in treating severe alopecia areata in adolescents, possibly due to profit-taking or market volatility rather than the implications of the study itself.

Eli Lilly & Co (LLY) stock fell by 0

Eli Lilly & Co (LLY) stock rose by 2.31% to $874.12, fueled by increased trading volume and interest in pharmaceutical stocks, as indicated by market activity involving high dollar volumes for leading pharmaceutical companies.

LLY

Latest News & Analysis